Top Stock Upgrades Today in the Buzz

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  11 May 2026
 

$AFRM
Bank of America analyst Matthew O’Neill raised his price target on Affirm Holdings to $88 from $82 while reiterating a Buy rating, citing what he described as a textbook beat-and-raise fiscal Q3 2026 report. Revenue came in at $1.04 billion, a 4% beat growing 33% year over year, and management lifted full-year guidance to a range of $4.175 billion to $4.205 billion. The Affirm Card continues to be the standout product with GMV up 146% year over year and 4.4 million active cardholders, representing ten consecutive quarters of roughly 30% GMV growth. O’Neill framed the stock’s recent pullback as a brief air pocket rather than a thesis crack, with the company’s investor forum on May 12 expected to provide a refreshed medium-term financial framework. The new target sits well above the Street consensus of $81.71, though investors should note that 30-day delinquencies have edged up to 3% and the allowance for credit losses has risen to 6% of loans held for investment, so the risk profile remains real at a 37x forward multiple.

$CC
RBC Capital analyst Arun Viswanathan raised his price target on Chemours Co to $29 from $26, maintaining an Outperform rating, with shares trading around $24.64 at the time of the call. Chemours operates in specialty chemicals with meaningful exposure to fluoroproducts and titanium technologies, areas that stand to benefit from a potential stabilization in industrial demand. The roughly 18% implied upside from the new target reflects a more constructive view on the company’s ability to navigate cost pressures, even as the broader chemicals space remains under pressure from weaker global manufacturing activity. The upgrade is measured rather than aggressive, but the maintained Outperform rating signals sustained conviction in the story at current prices.

$CRNX
Oppenheimer analyst Leland Gershell maintained an Outperform rating on Crinetics Pharmaceuticals, though he trimmed the price target modestly from $87 to $84, with shares trading around $36.55. The cut in target does not change the directional call, and the implied upside remains substantial given where the stock is currently priced. Crinetics is a clinical-stage biopharmaceutical company focused on rare endocrine diseases, and the maintained Outperform reflects continued confidence in the pipeline despite what is likely a near-term recalibration of timeline assumptions. For investors comfortable with binary clinical risk, the setup remains compelling at these levels relative to the analyst’s longer-term view.

$CVS
CVS Health received a price target hike to $103 from $102 at Wells Fargo, where analyst Stephen Baxter maintained an Overweight rating following the company’s Q1 2026 results, which topped estimates at $100.43 billion in revenue, a 6.17% year-over-year increase that beat expectations by more than $5 billion. The GAAP EPS of $2.30 also cleared the bar by $0.37. Separately, the company announced meaningful formulary changes effective July 1, shifting toward biosimilars over branded reference drugs including replacements for Stelara with two FDA-approved interchangeable alternatives. These moves are designed to reduce cost for plan sponsors and members, a strategically smart play in an environment where payers are scrutinizing drug spend. At a forward P/E of 11.45x and 88 hedge fund holders, CVS is among the more institutionally backed value names on today’s call sheet.

$JEF
Jefferies received attention on two fronts today. The firm itself was flagged in connection with an upgrade on ams OSRAM, where Jefferies analysts moved to a Buy rating on expectations of a coming AI and augmented reality upcycle that could drive a meaningful recovery in optical semiconductor demand. Meanwhile, Jefferies also appears in the broader undervalued stock conversation with the stock trading near $52.44 on modest volume. The AR and AI hardware cycle is an underappreciated tailwind for optical component makers, and Jefferies’ conviction here is notable given the firm’s research history in the semiconductor and hardware spaces. The $80 price target on the ams OSRAM call implies more than 52% upside, one of the more aggressive calls in today’s batch.

$OXY
Occidental Petroleum sits on the upgrade radar as a deep-value energy name with a forward P/E of just 9.92x, below the sector average of 12.58x. The Q1 2026 results showed $5.11 billion in revenue and a GAAP EPS of $3.13, topping consensus by $2.53 despite revenue coming in below expectations due to lower international output linked to Middle East disruptions. Free cash flow generation reached $1.7 billion before working capital in the quarter, a 52% increase driven by cost and operational efficiency. UBS maintains a Neutral but trimmed its target to $65 from $67, reflecting a cautious rather than bearish stance. Warren Buffett’s continued ownership gives the stock a credibility floor, and at current levels under $60, the valuation case is difficult to dismiss for patient energy investors.

$PR
Permian Resources rounds out the energy-heavy value portion of today’s upgrade activity, trading near $20.15 with an implied upside to $22 based on current analyst consensus. With the Permian Basin continuing to be the most productive and cost-efficient oil-producing region in North America, operators with strong acreage positions there remain well-positioned even in a more moderate oil price environment. The stock trades on below-average volume today relative to its 30-day average, suggesting the upgrade has not yet fully captured the market’s attention, which could represent an entry advantage for traders watching the name.

$SNAP
Snap appeared in the BofA research cycle today, though the primary focus of the note was on the broader fintech and consumer credit environment. The stock has been under sustained pressure, trading near $5.75 and down more than 5% on the session, with volume well below its 30-day average. The upgrade framing here is tentative, and while a Buy designation was applied, investors should weigh the ongoing monetization challenges, competitive pressure from TikTok and Instagram Reels, and the company’s historically uneven execution on advertising revenue. Any recovery in digital ad sentiment could offer a near-term bounce, but the fundamental rebuild will take time.

$TWLO
Twilio received an Oppenheimer upgrade to Buy today, with the stock trading near $198.59 after a modest pullback. The analyst community has been warming back up to Twilio as the company refocuses on its core communications platform business and demonstrates improved margin discipline after years of aggressive spending. The cloud communications space is seeing renewed enterprise interest in AI-powered customer engagement tools, an area where Twilio’s API infrastructure sits at a natural intersection. While no specific price target was reported in today’s data, the Oppenheimer Buy rating at current levels signals that the analyst sees the risk-reward as skewed to the upside from here, particularly if Twilio continues executing on profitability improvements.

$UPS
United Parcel Service rounds out the list as a classic value play with a forward P/E of 13.54x, meaningfully below the sector average of 20.46x and with 67 hedge fund holders providing institutional backing. Q1 2026 revenue came in at $21.28 billion, slightly down year over year but ahead of expectations by $228 million, with GAAP EPS of $1.20 beating by $0.02. The company reiterated full-year guidance of $89.7 billion in revenue and a non-GAAP adjusted operating margin of approximately 9.6%. UBS maintained its Buy rating while trimming the target to $123, noting that execution is the critical variable going forward. For investors seeking yield and stability alongside a genuine valuation discount to the sector, UPS makes a credible portfolio anchor even if near-term upside is more measured than some of the higher-beta names on today’s sheet.

View all market intelligence →